Global Pruritus Therapeutics 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR022510069

Publication Date:

February 27, 2025

Pages:

116

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Pruritus Therapeutics market size was valued at US$ 14690 million in 2024 and is forecast to a readjusted size of USD 19150 million by 2031 with a CAGR of 3.9% during review period.
Pruritus is a sensation that causes the desire or reflex to scratch. Pruritus has resisted many attempts to classify it as any one type of sensory experience. Modern science has shown that Pruritus has many similarities to pain, and while both are unpleasant sensory experiences, their behavioral response patterns are different. Pain creates a withdrawal reflex, whereas Pruritus leads to a scratch reflex.
In this report, we study the drugs for pruritus.
麻豆原创 competition is intense. J&J, Abbott, Amgen and LEO Pharma, etc. are the leaders of the industry, with about 60% market shares.
North America is the largest consumption place, with a revenue market share nearly 43%. Following North America, Europe is the second largest consumption place with the revenue market share of 27%.
This report is a detailed and comprehensive analysis for global Pruritus Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Pruritus Therapeutics market size and forecasts, in consumption value ($ Million), 2020-2031
Global Pruritus Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Pruritus Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Pruritus Therapeutics market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pruritus Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pruritus Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include J&J, Abbott, Amgen, LEO Pharma, Novartis, Bayer, Pfizer, UCB Pharma, GlaxoSmithKline, Galderma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Pruritus Therapeutics market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Antihistamines
Corticosteroids
Calcineurin Inhibitors
Others
麻豆原创 segment by Application
External Use
Oral
Injection
麻豆原创 segment by players, this report covers
J&J
Abbott
Amgen
LEO Pharma
Novartis
Bayer
Pfizer
UCB Pharma
GlaxoSmithKline
Galderma
Huapont
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Pruritus Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Pruritus Therapeutics, with revenue, gross margin, and global market share of Pruritus Therapeutics from 2020 to 2025.
Chapter 3, the Pruritus Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Pruritus Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Pruritus Therapeutics.
Chapter 13, to describe Pruritus Therapeutics research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Pruritus Therapeutics by Type
1.3.1 Overview: Global Pruritus Therapeutics 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Pruritus Therapeutics Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Antihistamines
1.3.4 Corticosteroids
1.3.5 Calcineurin Inhibitors
1.3.6 Others
1.4 Global Pruritus Therapeutics 麻豆原创 by Application
1.4.1 Overview: Global Pruritus Therapeutics 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 External Use
1.4.3 Oral
1.4.4 Injection
1.5 Global Pruritus Therapeutics 麻豆原创 Size & Forecast
1.6 Global Pruritus Therapeutics 麻豆原创 Size and Forecast by Region
1.6.1 Global Pruritus Therapeutics 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Pruritus Therapeutics 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Pruritus Therapeutics 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Pruritus Therapeutics 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Pruritus Therapeutics 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Pruritus Therapeutics 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Pruritus Therapeutics 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 J&J
2.1.1 J&J Details
2.1.2 J&J Major Business
2.1.3 J&J Pruritus Therapeutics Product and Solutions
2.1.4 J&J Pruritus Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 J&J Recent Developments and Future Plans
2.2 Abbott
2.2.1 Abbott Details
2.2.2 Abbott Major Business
2.2.3 Abbott Pruritus Therapeutics Product and Solutions
2.2.4 Abbott Pruritus Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Abbott Recent Developments and Future Plans
2.3 Amgen
2.3.1 Amgen Details
2.3.2 Amgen Major Business
2.3.3 Amgen Pruritus Therapeutics Product and Solutions
2.3.4 Amgen Pruritus Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Amgen Recent Developments and Future Plans
2.4 LEO Pharma
2.4.1 LEO Pharma Details
2.4.2 LEO Pharma Major Business
2.4.3 LEO Pharma Pruritus Therapeutics Product and Solutions
2.4.4 LEO Pharma Pruritus Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 LEO Pharma Recent Developments and Future Plans
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business
2.5.3 Novartis Pruritus Therapeutics Product and Solutions
2.5.4 Novartis Pruritus Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Novartis Recent Developments and Future Plans
2.6 Bayer
2.6.1 Bayer Details
2.6.2 Bayer Major Business
2.6.3 Bayer Pruritus Therapeutics Product and Solutions
2.6.4 Bayer Pruritus Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Bayer Recent Developments and Future Plans
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Pruritus Therapeutics Product and Solutions
2.7.4 Pfizer Pruritus Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Pfizer Recent Developments and Future Plans
2.8 UCB Pharma
2.8.1 UCB Pharma Details
2.8.2 UCB Pharma Major Business
2.8.3 UCB Pharma Pruritus Therapeutics Product and Solutions
2.8.4 UCB Pharma Pruritus Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 UCB Pharma Recent Developments and Future Plans
2.9 GlaxoSmithKline
2.9.1 GlaxoSmithKline Details
2.9.2 GlaxoSmithKline Major Business
2.9.3 GlaxoSmithKline Pruritus Therapeutics Product and Solutions
2.9.4 GlaxoSmithKline Pruritus Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 GlaxoSmithKline Recent Developments and Future Plans
2.10 Galderma
2.10.1 Galderma Details
2.10.2 Galderma Major Business
2.10.3 Galderma Pruritus Therapeutics Product and Solutions
2.10.4 Galderma Pruritus Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Galderma Recent Developments and Future Plans
2.11 Huapont
2.11.1 Huapont Details
2.11.2 Huapont Major Business
2.11.3 Huapont Pruritus Therapeutics Product and Solutions
2.11.4 Huapont Pruritus Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Huapont Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Pruritus Therapeutics Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Pruritus Therapeutics by Company Revenue
3.2.2 Top 3 Pruritus Therapeutics Players 麻豆原创 Share in 2024
3.2.3 Top 6 Pruritus Therapeutics Players 麻豆原创 Share in 2024
3.3 Pruritus Therapeutics 麻豆原创: Overall Company Footprint Analysis
3.3.1 Pruritus Therapeutics 麻豆原创: Region Footprint
3.3.2 Pruritus Therapeutics 麻豆原创: Company Product Type Footprint
3.3.3 Pruritus Therapeutics 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Pruritus Therapeutics Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Pruritus Therapeutics 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Pruritus Therapeutics Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Pruritus Therapeutics 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Pruritus Therapeutics Consumption Value by Type (2020-2031)
6.2 North America Pruritus Therapeutics 麻豆原创 Size by Application (2020-2031)
6.3 North America Pruritus Therapeutics 麻豆原创 Size by Country
6.3.1 North America Pruritus Therapeutics Consumption Value by Country (2020-2031)
6.3.2 United States Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Pruritus Therapeutics Consumption Value by Type (2020-2031)
7.2 Europe Pruritus Therapeutics Consumption Value by Application (2020-2031)
7.3 Europe Pruritus Therapeutics 麻豆原创 Size by Country
7.3.1 Europe Pruritus Therapeutics Consumption Value by Country (2020-2031)
7.3.2 Germany Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Pruritus Therapeutics Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Pruritus Therapeutics Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Pruritus Therapeutics 麻豆原创 Size by Region
8.3.1 Asia-Pacific Pruritus Therapeutics Consumption Value by Region (2020-2031)
8.3.2 China Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Pruritus Therapeutics Consumption Value by Type (2020-2031)
9.2 South America Pruritus Therapeutics Consumption Value by Application (2020-2031)
9.3 South America Pruritus Therapeutics 麻豆原创 Size by Country
9.3.1 South America Pruritus Therapeutics Consumption Value by Country (2020-2031)
9.3.2 Brazil Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Pruritus Therapeutics Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Pruritus Therapeutics Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Pruritus Therapeutics 麻豆原创 Size by Country
10.3.1 Middle East & Africa Pruritus Therapeutics Consumption Value by Country (2020-2031)
10.3.2 Turkey Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Pruritus Therapeutics 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Pruritus Therapeutics 麻豆原创 Drivers
11.2 Pruritus Therapeutics 麻豆原创 Restraints
11.3 Pruritus Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Pruritus Therapeutics Industry Chain
12.2 Pruritus Therapeutics Upstream Analysis
12.3 Pruritus Therapeutics Midstream Analysis
12.4 Pruritus Therapeutics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

J&J
Abbott
Amgen
LEO Pharma
Novartis
Bayer
Pfizer
UCB Pharma
GlaxoSmithKline
Galderma
Huapont

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.